Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
ASH 2020 | TRANSCEND CLL 04: 18-month follow-up of liso-cel for R/R CLL
Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the findings of a trial (NCT03386513) of IMGN632, a novel antibody-drug conjugate (ADC), in relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN), a setting with poor outcomes and minimal treatment options.
ASH 2020 | Phase I trial of decitabine plus ipilimumab in R/R MDS & AML
Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a Phase I trial (NCT02890329) of decitabine (DAC) in combination with ipilimumab (IPI) in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML), with or without prior allogeneic hematopoietic cell transplantation (allo-HCT).
EHA-SWG Scientific meeting on Immunotherapy: Checkpoint inhibition in hematologi...
Selected from the latest EHA-SWG Scientific Meeting on Immunotherapy, we present two lectures covering the use of immune checkpoint inhibitors (ICIs) in hematology. Peter Brossart explains the mechanism of action of these drugs and Paul Bröckelmann gives an updated overview of approved and emerging indications.
CAR T-Cell Therapy Improves Blood Cancer, But Toxicities Are Still Concerning
In an interview with OncLive, during the 2020 Institutional Perspectives in Cancer webinar on Leukemia and Lymphoma, Olalekan O. Oluwole, MBBS, MD, who is an assistant professor of medicine, hematology, and oncology at Vanderbilt-Ingram Cancer Center, highlighted the evolution of CAR T-cell therapy in leukemia and lymphoma, targets under investigation, and next steps for exploration.
Highlights in the myeloma field to come at ASH 2020
Enrique M. Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, shares what highlights there are to look forward to in the multiple myeloma field at ASH 2020
iwCAR-T meeting 2020: featured sessions
During iwCAR-T 2020, some of the world’s leading clinical researchers shared their perspectives on how to place our evolving understanding in a clinical context and thereby optimize clinical care.
Should all Elderly Patients with Newly Diagnosed Multiple Myeloma Receive Monoc...
In light of the recent approvals of combination anti-myeloma regimens containing monoclonal antibodies, as well as the robust pipeline of novel targeted agents likely to be approved in the next year, there is much optimism in the field of multiple myeloma.
CAR T-Cell Combinations May Offer a Way to Overcome Antigen Escape in MCL
Joshua Brody, MD, discusses advances made with CAR T-cell therapy in MCL, the promise of venetoclax in B-cell malignancies, and the potential for bispecific antibody combination regimens in this disease.
EHA and EBMT join forces in the GoCART coalition to advance cellular therapy in ...
EHA joins EBMT in a newly founded GoCART coalition aimed at positioning Europe in the lead of the global cellular therapy field for hematological diseases. GoCART aims to promote patient access to novel cellular therapies and to contribute health and well-being through innovation by multi-stakeholder collaboration.
CAR T-Cell Research Surges
Research on chimeric antigen receptor (CAR) T-cell therapies has exploded since the first such treatment received approval in 2017. Hundreds of trials are under way, 3 therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma (MM).